Avalon GloboCare Corp.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US05344R2031
USD
1.46
0.13 (9.77%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Avalon GloboCare Corp. stock-summary
stock-summary
Avalon GloboCare Corp.
Pharmaceuticals & Biotechnology
Avalon GloboCare Corp. is an intelligent biotech developer and healthcare service provider. The Company engages in the management of stem cell banks and specialty clinical laboratories. It is developing of exosome technology to improve the diagnosis and management of diseases. The Company operates through two platforms, Avalon Cell and Avalon Rehab. Its technology and service ecosystem covers the areas of regenerative medicine, cell-based immunotherapy, exosome technology, as well as rehabilitation medicine. The Company also focused on diagnostic advancements in the fields of oncology, infectious diseases and fibrotic diseases, and the discovery of disease-specific exosomes to provide the disease origin insight necessary to enable.
Company Coordinates stock-summary
Company Details
4400 US Highway 9 Ste 3100 , FREEHOLD NJ : 07728-4210
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 3 Schemes (0.9%)

Foreign Institutions

Held by 4 Foreign Institutions (0.12%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Lu Wenzhao
Chairman of the Board of Directors
Dr. David Jin
President, Chief Executive Officer, Director
Ms. Li Meng
Chief Operating Officer, Secretary, Director
Mr. Wilbert Tauzin
Director
Mr. Steven Sanders
Independent Director
Mr. William Stilley
Independent Director
Dr. Tevi Troy
Independent Director
Mr. Lu Yancen
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2025)
Net Profit:
-13 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 9 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.14

stock-summary
Return on Equity

167.00%

stock-summary
Price to Book

-1.27